Percutaneous treatment with Mitraclip for functional mitral regurgitation: medium-term follow up according to left ventricular function.
Functional
Mitraclip
left ventricular function
mitral regurgitation
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
entrez:
21
9
2020
pubmed:
22
9
2020
medline:
22
9
2020
Statut:
ppublish
Résumé
Functional mitral regurgitation (FMR) is a bad prognosis condition despite optimal medical treatment. Nowadays there is an open debate about the surgical versus percutaneous treatment. The main objective of this study is to evaluate the mid-term follow up clinical outcomes of patients with FMR treated with MitraClip Data was obtained from two experienced centers in transcatheter mitral valve repair (TMVR). All consecutive cases of severe FMR undergoing TMVR in both centers with the same inclusion criteria were included prospectively in this study and followed-up. Periodical follow-ups with clinical and echocardiographic evaluation were scheduled from the baseline procedure, at 3 months and then yearly. From October 2015 to October 2019, a total of 119 patients with FMR at 2 centers in Spain underwent TMVR with the MitraClip The MitraClip edge-to-edge technique is a safe and effective procedure for the treatment of FMR. In this study, patients with LVEF >30% treated with Mitraclip presented better clinical cardiovascular outcomes than those with a LVEF ≤30%. Regardless clinical outcomes, at the end of the follow-up, there was a sustained reduction in MR grades and an important improvement in NYHA functional class.
Sections du résumé
BACKGROUND
BACKGROUND
Functional mitral regurgitation (FMR) is a bad prognosis condition despite optimal medical treatment. Nowadays there is an open debate about the surgical versus percutaneous treatment. The main objective of this study is to evaluate the mid-term follow up clinical outcomes of patients with FMR treated with MitraClip
METHODS
METHODS
Data was obtained from two experienced centers in transcatheter mitral valve repair (TMVR). All consecutive cases of severe FMR undergoing TMVR in both centers with the same inclusion criteria were included prospectively in this study and followed-up. Periodical follow-ups with clinical and echocardiographic evaluation were scheduled from the baseline procedure, at 3 months and then yearly.
RESULTS
RESULTS
From October 2015 to October 2019, a total of 119 patients with FMR at 2 centers in Spain underwent TMVR with the MitraClip
CONCLUSIONS
CONCLUSIONS
The MitraClip edge-to-edge technique is a safe and effective procedure for the treatment of FMR. In this study, patients with LVEF >30% treated with Mitraclip presented better clinical cardiovascular outcomes than those with a LVEF ≤30%. Regardless clinical outcomes, at the end of the follow-up, there was a sustained reduction in MR grades and an important improvement in NYHA functional class.
Identifiants
pubmed: 32953759
doi: 10.21037/atm.2020.02.122
pii: atm-08-15-959
pmc: PMC7475438
doi:
Types de publication
Journal Article
Langues
eng
Pagination
959Informations de copyright
2020 Annals of Translational Medicine. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.02.122). The series “Structural Heart Disease: The Revolution” was commissioned by the editorial office without any funding or sponsorship. CGC reports personal fees from ABBOT VASCULAR, outside the submitted work. REL reports personal fees from ABBOT VASCULAR, outside the submitted work. TBG reports grants from ABBOT VASCULAR, outside the submitted work. DHV served as the unpaid Guest Editor of the series and serves as an unpaid editorial board member of Annals of Translational Medicine from Aug 2019 to Jul 2021. The authors have no other conflicts of interest to declare.
Références
Rev Esp Cardiol (Engl Ed). 2020 Aug;73(8):643-651
pubmed: 31732437
J Am Coll Cardiol. 2015 Mar 31;65(12):1231-1248
pubmed: 25814231
JAMA Cardiol. 2017 Oct 1;2(10):1130-1139
pubmed: 28877291
Circulation. 2013 Apr 9;127(14):1485-92
pubmed: 23459614
N Engl J Med. 2018 Dec 13;379(24):2297-2306
pubmed: 30145927
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
N Engl J Med. 2018 Dec 13;379(24):2307-2318
pubmed: 30280640
Eur Heart J. 2003 Jul;24(13):1231-43
pubmed: 12831818
Circulation. 2014 Dec 2;130(23):2012-20
pubmed: 25355912
Eur Heart J. 2016 Feb 21;37(8):703-12
pubmed: 26614824
J Am Coll Cardiol. 2013 Sep 17;62(12):1052-1061
pubmed: 23747789
Circulation. 1994 Aug;90(2):830-7
pubmed: 8044955
JACC Cardiovasc Imaging. 2019 Feb;12(2):353-362
pubmed: 30553663
N Engl J Med. 2011 Apr 14;364(15):1395-406
pubmed: 21463154
J Am Coll Cardiol. 2014 Dec 30;64(25):2792-801
pubmed: 25541133
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242
Circulation. 2012 May 29;125(21):2639-48
pubmed: 22553307
J Am Coll Cardiol. 2014 Sep 2;64(9):875-84
pubmed: 25169171
Rev Esp Cardiol (Engl Ed). 2020 Jul;73(7):530-535
pubmed: 31405796
Eur J Heart Fail. 2012 Sep;14(9):1050-5
pubmed: 22685268
J Am Soc Echocardiogr. 2017 Apr;30(4):303-371
pubmed: 28314623
Can J Cardiol. 2014 Sep;30(9):962-70
pubmed: 24986049
Eur Heart J. 2018 Jan 1;39(1):39-46
pubmed: 29020337